Submission Deadline ( Vol 71 , Issue 01 )
17 Jan 2026Publish On ( Vol 71 , Issue 01 )
31 Jan 2026Chinese Science Bulletin (ISSN:0023-074X) and (E-ISSN:2095-9419) is a monthly peer-reviewed scopus indexed journal originally from 1963 to 1964, from 1980 to 1984, 1989, from 2015 to Present. The publisher of the journal is Editorial Office of Journal of Science China Press.The journal welcomes all kind of research/review/abstract papers regarding Multidisciplinary subjects.
AIM AND SCOPE
1.Agricultural Science/Agricultural Engineering
2.Electrical Engineering and Telecommunication Section
3.Computer Science and Engineering
4.Civil and Architectural Engineering Section
5.Mechanical and Materials Engineering Section
6.Chemical Engineering Section
7.Food Engineering Section
8.Physics Section
9.Mathematics Section
10.Accounting and finance
11.Economics
12.Management
13.Social science
14.Earth science
15.Law
16.Linguistics
17.Biological science
18.Environmental science
19.Material science
20.zoology
21.Fishery and Science
22.Psychology
23.International Business
24.HRM
25.Marketing
26.History
27.Public health
28.Botany
ALL PUBLISH JOURNAL HERE
CSB-15-01-2024-1150
/
Chinese Science Bulletin
Acoustic metamaterials are materials with artificially designed structures, which have characteristics that surpass the behavior of natural materials, such as negative refraction, anomalous Doppler effect, plane focusing, etc. This article mainly introduces and summarizes the related research progress of acoustic metamaterials in the past two decades, focusing on meta-atomic acoustic metamaterials, metamolecular acoustic metamaterials, meta-atomic clusters and metamolecule cluster acoustic metamaterials. Finally, the research overview and development trend of acoustic metasurfaces are brief
CSB-15-01-2024-1149
/
Chinese Science Bulletin
Boron neutron capture therapy (BNCT) is a tumor-selective particle radiotherapy. It combines preferential boron accumulation in tumors and neutron irradiation. The recent initiation of BNCT clinical trials employing hospital-based accelerators rather than nuclear reactors as the neutron source will conceivably pave the way for new and more numerous clinical trials, leading up to much-needed randomized trials. In this context, it would be interesting to consider the implementation of new boron compounds and strategies that will significantly optimize BNCT. With this aim in mind, we analyzed,
CSB-15-01-2024-1148
/
Chinese Science Bulletin
In this article, a novel method of simultaneous carborane- and gadolinium-containing compounds as efficient agents for neutron capture therapy (NCT) delivery via magnetic nanocarriers is presented. The presence of both Gd and B increases the efficiency of NCT and using nanocarriers enhances selectivity. These factors make NCT not only efficient, but also safe. Superparamagnetic Fe3O4 nanoparticles were treated with silane and then the polyelectrolytic layer was formed for further immobilization of NCT agents. Fourier-transform infrared spectroscopy (FTIR), X-ray diffraction (XRD), energy di
CSB-15-01-2024-1147
/
Chinese Science Bulletin
Boron neutron capture therapy (BNCT) is a binary modality that is used to treat a variety of malignancies, using neutrons to irradiate boron-10 (10B) nuclei that have entered tumor cells to produce highly linear energy transfer (LET) alpha particles and recoil 7Li nuclei (10B [n, α] 7Li). Therefore, the most important part in BNCT is to selectively deliver a large number of 10B to tumor cells and only a small amount to normal tissue. So far, BNCT has been used in more than 2000 cases worldwide, and the efficacy of BNCT in the treatment of head and neck cancer, malignant meningioma, me
CSB-15-01-2024-1146
/
Chinese Science Bulletin
Boron neutron capture therapy (BNCT) is a binary cancer treatment that involves the irradiation of 10B-containing tumors with low-energy neutrons (thermal or epithermal). The alpha particles and recoiling Li nuclei that are produced in the 10B-capture nuclear reaction are high-linear-energy transfer particles that destroy boron-loaded tumor cells; therefore, BNCT has the potential to be a localized therapeutic modality. Two boron-delivery agents have been used in clinical trials of BNCT in patients with malignant brain tumors, cutaneous melanoma, or recurrent tumors of the head and neck reg